UK markets open in 1 hour 9 minutes

Coya Therapeutics, Inc. (COYA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
7.99-0.01 (-0.13%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.00
Open8.14
Bid7.81 x 100
Ask8.11 x 100
Day's range7.82 - 8.38
52-week range3.21 - 10.69
Volume37,500
Avg. volume96,720
Market cap116.672M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.79
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.00
  • Business Wire

    Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

    HOUSTON, April 22, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer and Chairman of the Board Howard Berman, Ph.D., and Chief Business Development Officer Arun Swaminathan, Ph.D., will participate in the Mizuho Neuroscience Summit being held May 20 – 21 at the Boston Harbor Hotel. Drs. Berman and Swaminathan will also be

  • Business Wire

    Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

    HOUSTON, April 18, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston.

  • Business Wire

    Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

    HOUSTON, April 08, 2024--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board, and Dr. David Beers, Ph.D., Associate Research Professor of Neurology, Houston Methodist, will present updated ALS biomarker data at the upcoming 2nd Annual Johnson Center Symposium in Houston, Texas on April